Asthma: Airway Pathophysiology, Inflammatory Endotypes, Diagnostic Testing, and Stepwise Management
A pulmonology reference on the three mechanisms of airflow obstruction, the type 2 high and type 2 low inflammatory endotypes, objective diagnostic testing with its numeric thresholds, GINA Track 1 stepwise management, and acute exacerbation care.
Submitted research brief - Submitted to OwieClear; written with an AI assistant - November 2026
Read this first. This document was written outside OwieClear and has not been reviewed by a clinician. We publish it so you can read the source for yourself. It is educational and is not medical advice. Where our own pages disagree with it, follow our pages, which cite their sources, and ask a healthcare professional about anything that affects your care.
What we found that needs correcting
- This is one of the stronger briefs we have published. It is aligned with current GINA guidance, it leads with the single most important change in modern asthma care, and its numeric thresholds are correct. The notes below are omissions and points of emphasis rather than errors of fact.
- The montelukast boxed warning is missing, and that is the most important safety gap. The brief lists montelukast as a Step 4 add-on without mentioning that the FDA required a boxed warning in 2020 about serious mental health side effects, including agitation, aggression, depression, sleep disturbance and suicidal thinking and behaviour. The FDA also advised that it should generally be reserved for people who have not responded to or cannot tolerate other treatments, particularly for allergic rhinitis. Anyone reading a list that includes this drug needs to know what to watch for.
- GINA Track 2 is not mentioned. The brief presents Track 1 as the management pathway, which is correct as the preferred route, but Track 2, in which a daily inhaled corticosteroid is combined with a short-acting reliever, is the alternative for people who cannot or will not use ICS-formoterol as a reliever. Omitting it leaves no option for a reader whose own prescription looks different.
- Children under twelve are not covered, and the pathway for them differs. The brief states that recommendations apply to adolescents and adults, which is accurate, but a reader with a young child will not find that distinction easily. Younger children are generally prescribed a daily inhaled corticosteroid with a separate reliever, and dosing, device choice and growth monitoring all differ.
- Licensing differs by country, and this matters for a US audience. As-needed ICS-formoterol is the GINA preferred reliever worldwide, but formoterol-containing combinations are not FDA-approved for that as-needed use in the United States, even though it is widely recommended by US specialists. What the FDA did approve, in 2023, is albuterol-budesonide as an as-needed anti-inflammatory reliever. A reader whose prescription does not match the brief is not necessarily being treated wrongly.
- Inhaler technique is named once, in a clause, and deserves far more weight. Studies consistently find that a large proportion of people use their inhalers incorrectly enough to reduce the delivered dose substantially, and that this is a common reason for apparently uncontrolled asthma. A spacer with a metered-dose inhaler markedly increases lung delivery. Before any dose is stepped up, technique should be observed directly.
- There is nothing on the written asthma action plan, which is the main self-management tool in every major guideline. A plan that sets out what to do when well, when symptoms worsen, and when to seek emergency care is associated with better outcomes, and audits of asthma deaths repeatedly find that the person did not have one.
- The history behind the SABA-only recommendation is worth stating, because it explains the rule. Epidemics of asthma deaths in the 1960s and again in New Zealand in the 1970s and 1980s were linked to potent relievers, and the mechanism was understood to be over-reliance on symptom relief while the underlying inflammation worsened. The brief gives the correct recommendation without the reason that makes it memorable: frequent reliever use is a marker of risk of death, not merely of poor control.
- Oral corticosteroids are presented as the last option before biologics, which is correct, without their cumulative harms. Repeated or long-term courses carry risks of osteoporosis and fracture, diabetes, cataracts and glaucoma, adrenal suppression, weight gain, hypertension and skin thinning. Avoiding them is a large part of why biologics are used, and the brief should say so.
- Macrolides are endorsed for type 2 low asthma more briefly than the evidence warrants. Long-term azithromycin does have trial support as an add-on in persistent uncontrolled asthma, but it requires screening for QT prolongation and non-tuberculous mycobacteria, carries risks to hearing, and raises antibiotic resistance. It is specialist-directed, not a general option.
- Trigger management is reduced to the phrase trigger avoidance. The practical items are worth naming: smoking and vaping cessation, which also restores steroid responsiveness; annual influenza vaccination, given that viral infection triggers most exacerbations; treatment of allergic rhinitis and sinus disease, which often improves asthma control; damp and mould remediation; and asking directly about aspirin and other anti-inflammatory painkillers, which can cause severe reactions in aspirin-exacerbated respiratory disease, a condition the brief names but does not warn about.
- Occupational asthma is listed as a risk factor for the type 2 low endotype but not as a cause with its own management. It is a genuinely distinct situation: identifying the workplace agent and removing the person from exposure early can prevent permanent airflow obstruction, and delay reduces the chance of recovery.
- Follow-up after an exacerbation is not mentioned. Review within one to two weeks of an attack, with reassessment of control, technique and the action plan, is a standard recommendation and one of the most frequently missed steps in real practice.
- The differential diagnosis is absent, and the brief's own strong insistence on objective testing implies its importance. Conditions that mimic asthma include inducible laryngeal obstruction, which is commonly misdiagnosed as severe asthma and does not respond to inhalers; heart failure; COPD; bronchiectasis; ACE inhibitor cough; and, in a young child with sudden-onset wheeze, an inhaled foreign body, which is a time-critical emergency.
- A note on the acute management section: the drug doses given are correct for clinicians and are not instructions for home use. OwieClear does not publish doses. Readers should treat that section as a description of what a hospital does, not as something to act on.
- Everything else in the brief is accurate. The three mechanisms of obstruction, with smooth muscle hypertrophy, goblet cell hyperplasia and basement membrane fibrosis leading to fixed obstruction; the endotype table, including the association of non-allergic eosinophilic asthma with nasal polyposis and aspirin-exacerbated respiratory disease; the mechanism and five-to-fifteen-minute timing of exercise-induced bronchoconstriction; the spirometry, peak flow variability, challenge testing and biomarker thresholds; the stepwise Track 1 structure through to biologic phenotyping; and the acute severity markers, including drowsiness, confusion and a silent chest as signs of impending respiratory arrest, are all correctly stated.
Download the PDF
Our reviewed pages on this
All source documents